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Abstract
Background: Emergence of antibacterial resistance and production of Extended spectrum β-lactamases (ESBLs) are
responsible for the frequently observed empirical therapy failures. Most countries have experienced rapid dissemination
of ESBLs producing Enterobacteriaceae isolates, particularly E. coli and Klebsiella pneumoniae. ESBLs are clinically significant
and when detected, indicate the need for the use of appropriate antibacterial agents. But antibacterial choice is often
complicated by multi-resistance.
Methods: This study was carried from June to November 2014 to study the multidrug resistant (MDR) Enterobacteriaceae
and ESBL producing E. coli among urine isolates in hospital setting. Isolates from urine samples were primarily screened
for possible ESBL production followed by phenotypic confirmation. Antibiotic susceptibility testing (AST) was done by
Kirby Bauer disk diffusion method following Clinical and Laboratory Standard Institute (CLSI) guidelines.
Results: Out of 450 urine samples processed, 141 significant growths were obtained including 95 Enterobacteriaceae
isolates with 67 E. coli. Among Enterobacteriaceae, 92 (96.84 %) were recorded as MDR and 18 (26.87 %) E. coli were
confirmed as ESBLs producers.
Conclusions: Using the phenotypic confirmatory test forwarded by the CLSI, relatively significant E. coli isolates tested
were ESBL producers. Also high numbers of MDR organisms were isolated among Enterobacteriaceae. Isolates showed
significant resistance to the commonly prescribed drugs. These findings suggest for further study in this field including
the consequences of colonization with MDR and ESBL-producing bacteria both in the community and in the hospital
setting.
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Background
Urinary tract infection (UTI) is a common disease ailment
among Nepalese population as well as one of the com-
monest nosocomial infection [1]. Because of the evolving
and continuing antibiotic resistance phenomenon, regular
monitoring of resistance patterns is necessary to improve
guidelines for empirical antibiotic therapy [2]. Uropatho-
gens have developed resistance to commonly prescribed
antimicrobial agents; this severely limits the treatment
options of an effective therapy. One of the important
resistance mechanisms is production of enzymes destroy-
ing the drug β-lactam antibiotics. To date several types of
β-lactamases have been characterized depending on the
characteristic and hydrolytic activity. Extended spectrum
β-lactamases (ESBLs) is one of the important groups of β-
lactamases [3].
ESBLs are the enzymes that have the ability to
hydrolyze and cause resistance to various types of
newer β-lactam antibiotics, including the expanded-
spectrum (or third generation) cephalosporins (eg. cef-
otaxime, ceftriaxone, ceftazidime) and monobactams
(eg. aztreonam), but not the cephamycins (eg. cefoxitin
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and cefotetan) and carbapenems (eg. imipenem, merope-
nem and etrapenem) [4]. These enzymes are sensitive to
β-lactamase inhibitors (sulbactam, clavulanic acid, and taz-
obactam) [5].
A large number of outbreaks of the infections which
are caused by ESBL producing organisms have been
described in every continent of the globe [5]. There is
ample evidence to suggest the spread of ESBL infec-
tions is higher in resource poor countries [6]. Major
risk factors for colonization or infection with ESBL
producing organisms are long term antibiotic expos-
ure, prolonged intensive care unit (ICU) stay, nursing
home residency, severe illness, residence in an institu-
tion with high rates of ceftazidime and other third
generation cephalosporin use and instrumentation or
catheterisation [7].
E. coli, that can produce ESBLs, has arisen and dissem-
inated worldwide as an important cause of both nosoco-
mial and community infections and nowadays represents
a major threat. Early identification of potential ESBL car-
riers is the first step to withhold the dispersal of these
microorganisms and to avoid possible complications [8].
Since, ESBL production is usually plasmid mediated, it is
possible for one specimen to contain both ESBL produ-
cing and non ESBL producing cells of the same species.
This suggests that for optimal detection, several colonies
must be tested from a primary culture plate [7]. Adequate
detection of ESBL-producing strains is crucial for appro-
priate choice of antimicrobial therapy and infection con-
trol measures [9].
MDR Enterobacteriaceae has been frequently reported
from different parts of the world as an emergence of
treatment problem. Antibiotics given empirically without
proper antibiotic susceptibility testing are one of the
major causes for the development of MDR. So, to ensure
appropriate therapy, current knowledge of the organism
that causes UTI and their antibiotic susceptibility is
mandatory [10]. The dissemination of ESBL-producing
Enterobacteriaceae in the hospital setting is a problem
with major therapeutic and epidemiological consequences
[11]. This study was aimed to investigate the current situ-
ation of ESBL-producing Escherichia coli among Entero-
bacteriaceae isolates and sensitivity pattern of isolates
toward various chemotherapeutic agents.
Methods
Sample
This is a cross-sectional study conducted from June to
November 2014 in National Kidney Center, Vanasthali,
Kathmandu, Nepal. The study population included pa-
tients visiting the hospital suspected of UTIs and pa-
tients undergoing dialysis in the hospital.
Patients included in the study were given pre-labelled
(date, time, identification code, age and sex), leak proof,
sterile, screw-capped container to collect the mid-stream
urine (MSU) sample. Urine samples from all age group
were included in the study. Samples those held for more
than two hours at room temperature and those without
proper labelling were excluded from the study.
Laboratory assessment
The collected urine specimens were processed in the
Microbiology laboratory within 2 h of collection. Urine
samples were streaked directly on MacConkey agar
(MA) and Blood agar (BA) plates. These plates were in-
cubated at 37 °C aerobically and after overnight incuba-
tion, they were checked for bacterial growth. The Gram
negative isolates were identified by their colony morph-
ology, Gram staining characteristics, catalase test, oxi-
dase test, and other relevant biochemical tests as per
standard laboratory methods of identification.
Antibiotic susceptibility testing of bacterial isolates
was done by Kirby Bauer disk diffusion method follow-
ing CLSI guidelines using Mueller Hilton Agar (MHA)
[12]. The discs were taken from HiMedia Laboratories
(India). The followings are the concentrations of drugs
used for disc diffusion testing: amikacin (30 μg), cefa-
lexin (30 μg), cefixime (5 μg), cefotaxime (30 μg), ceftazi-
dime (30 μg), ceftriaxone (30 μg), ciprofloxacin (5 μg),
cotrimoxazole (23.75 μg sulfamethoxazole/1.25 μg tri-
methoprim), doxycycline (30 μg), imipenem (10 μg),
nalidixic acid (30 μg), nitrofurantoin (300 μg), Norfloxa-
cin (10 μg), and ofloxacin (5 μg). An isolate was consid-
ered as MDR if it was resistant to three or more drugs
of different classes/groups of antibiotics.
ESBL detection
All the E. coli isolates were subjected to the screening
test for ESBL detection. Screening test for ESBL detec-
tion was done according to the CLSI guidelines [12]. Iso-
lates showing inhibition zone size of ≤ 22 mm with
ceftazidime (30 μg), ≤ 25 mm with ceftriaxone (30 μg),
and ≤ 27 mm with cefotaxime (30 μg) were interpreted
as screening test positive for ESBL production.
For the confirmatory test for ESBL, two or three col-
onies of organisms were suspended in 0.5 ml of sterile
broth and the turbidity matched to 0.5 McFarland. Using
a sterile cotton swab the broth culture was uniformly
swabbed on MHA. All the E. coli isolates which were re-
sistant to at least ceftazidime, ceftriaxone and/or cefo-
taxime were subjected to the ESBL confirmatory test
using ceftazidime (30 μg) and ceftazidime-clavulanic acid
(30 μg + 10 μg) and the cefotaxime (30 μg) and cefotaxime-
clavulanic acid (30 μg + 10 μg) combination disks. The tests
were interpreted according to CLSI guidelines and a differ-
ence of 5 mm between zone of inhibition of a single disk
and in combination with clavulanic acid (inhibitor) was
confirmed to be produced by an ESBL positive isolate.
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Results
Out of 450 urine samples processed in the laboratory,
growth on MA and/or BA was obtained in 141 (31.33 %)
urine samples (Table 1). Highest number of isolates was
from the sample of patients with age above 60 years.
Among the isolates (n = 141) 41 (29.08 %) were Gram
positive organism and 100 (70.92 %) were Gram negative
organisms (Table 2). S. aureus and E. coli were the most
predominant organism among Gram positive and Gram
negative respectively. Out of 100 Gram negative organ-
isms, 95 (95 %) were of Enterobacteriaceae family. E. coli
was the most predominant genera of Enterobacteriaceae
followed by Klebsiella spp, Proteus spp and Citrobacter
spp. E. coli was isolated in 67 (47.52 %) samples. Other
Gram negative organisms isolated were Pseudomonas
spp and Neisseria spp.
The resistance of Enterobacteriaceae isolates against a
spectrum of 14 selected antimicrobial agents of different
classes were analyzed (Table 3). Enterobacteriaceae iso-
lates showed variable result in their antibiotic sensitivity
pattern against commercial antibiotic discs tested. Ac-
cording to the susceptibility pattern imipenem (92.63 %)
was the most effective antibiotics against Enterobacteria-
ceae followed by the amikacin (82.11 %) and nitrofuran-
toin (57.89 %). Out of 14 antibiotics tested, 11 were found
effective only for less than half of the Enterobacteriaceae
isolates. Among the 95 Enterobacteriaceae isolates none
of them were sensitive to all antibiotics tested.
Seventy three varied patterns of the antibiotic suscepti-
bility were observed among the enterobacteriaceae isolates
against the 14 different antibiotics. Each of these patterns
was common in one or up to eight isolates which were an-
alyzed. Enterobacteriaceae isolates include 67 E. coli, 24
Klebsiella spp, 3 Proteus spp. and one Citrobacter spp. Out
of 95 Enterobacteriaceae, 92 (96.84 %) isolates were MDR
(Table 4). Sixty four (95.52 %) isolates of E. coli and all iso-
lates of Klebsiella spp, Proteus spp and Citrobacter spp
were detected as MDR.
Out of total 67 strains of E. coli, which were screened for
ESBL production, 53 (79.10) isolates were positive. All the
E. coli isolates which were resistant to at least ceftazidime,
ceftriaxone and/or cefotaxime were considered as screening
positive isolates. After performing phenotypic confirmation
test 18 (26.87 %) E. coli isolates were confirmed as ESBL
producers (Fig. 1).
ESBL positive E. coli showed high degree of resistance
to the antibiotics tested. All 18 ESBL positive E. coli iso-
lates were resistant (100 %) to cefotaxime, ceftazidime and
ceftriaxone (Table 5). These isolates also showed high re-
sistance to other antibiotics as well. More than 60 % of
ESBL positive isolates were resistant to 11 antibiotics out
14 antibiotics used for test. Most effective drug for the
ESBL positive isolates was amikacin, to which all (100 %)
isolates were susceptible. Amikacin was followed by imi-
penem (94.44 %) and nitrofurantoin (72.22 %).
High degree of resistance was shown by ESBL producers
than ESBL non producers (Fig. 2). Only in case of cotri-
moxazole, nitrofurantoin, imipenem and amikacin ESBL
non producers showed a bit higher resistance than ESBL
producers. Most effective drug for the ESBL non pro-
ducers was found to be imipenem which was susceptible
to 45 (91.84 %) out of 49 isolates, followed by amikacin
susceptible to 35 (71.43 %) isolates and nitrofurantoin sus-
ceptible to 34 (69.39 %) isolates.
Discussion
This study was aimed to investigate ESBL-producing E. coli
among Enterobacteriaceae isolates and sensitivity pattern of
isolates toward various chemotherapeutic agents. Organ-
isms producing ESBLs are clinically relevant and remain an
important cause of failure of therapy with cephalosporins.
ESBLs are primarily produced by the Enterobacteriaceae
family, in particular K. pneumoniae and E. coli. Bacteria
harbouring ESBLs may also acquire and most often exhibit
additional resistances to other antimicrobial classes such as
the quinolones, tetracyclines, cotrimoxazole, trimethoprim,
and aminoglycosides, which further limits therapeutic op-
tions and thus pose a therapeutic dilemma [13].
Significant growth was obtained in 31.33 % urine culture
samples. The majority of urine specimens showed no
growth (68.67 %). The possible cause of low rate of growth
positivity might be due to urine samples obtained from pa-
tients on antibiotics therapy, infection due to slow growing
organisms or due to those organisms that were not able to
grow on the routine media used [1, 14]. Number of female
patients requesting for urine culture was higher than the




Sample Growth (%) Sample Growth (%) Sample Growth (%)
≤ 20 13 1 (1.79) 13 8 (9.41) 26 9 (6.38)
21 – 40 45 16 (28.57) 89 24 (28.24) 134 40 (28.37)
41 – 60 79 18 (32.14) 81 22 (25.88) 160 40 (28.37)
≥ 61 68 21 (37.50) 62 31 (36.47) 130 52 (36.88)
Total 205 56 (100) 245 85 (100) 450 141 (100)
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male patients. Significant microbial growth was higher in
case of female than in male. Urethral opening in females,
short urethra and complicated physiology especially during
pregnancy can be considered as reason [15]. Female pa-
tients requesting for urine culture was higher, than the
male patients, in age group of 21–40 years this may be be-
cause this age group consists sexually active women. Fre-
quent or recent sexual activity is the most important risk
factor for UTIs in young women. Nearly 80 % of all UTIs
in premenopausal women occur within 24 h of intercourse.
UTIs are very rare in celibate women. Certain types of con-
traceptives can also increase the risk of UTIs [16].
Numbers of gram negative organisms isolated were
much higher than the gram positive. Similar predomin-
ance of gram negative organism in urine sample has
been observed by other researchers too [17, 18].
Staphylococcus aureus, Coagulase-negative staphylococci
(CoNS) and Enterococcus spp. were the gram positive or-
ganisms isolated. E. coli, Klebsiella spp., Proteus spp.,
Citrobacter spp., Pseudomonas spp. and Neisseria spp.
were the gram negative organisms isolated. Among the
gram negative organisms, Enterobacteriaceae were most
frequent, 95 out of 100 gram negative organisms. Mem-
bers of Enterobacteriaceae are more likely to cause UTIs
than other organisms. In various studies predominant
organisms isolated in UTI cases is Enterobacteriaceae
[17, 19, 20].
Antibiotic susceptibility pattern shown by the Entero-
bacteriaceae isolates were variable. Imipenem was the
most effective antibiotic as 92.63 % of isolates were sus-
ceptible, followed by amikacin (82.11 %). Isolates were
comparatively less susceptible to cephalosporins than
other antibiotics. Resistance to β-lactams in Enterobacte-
riaceae is mainly due to the production of β-lactamases,
which may be encoded either chromosomally or on
Fig. 1 ESBL production profile of E. coli isolates
Table 3 Antimicrobial resistance amongst Enterobacteriaceae
(n = 95)
Antibiotics class Antibiotics Resistance no. (%)
Aminoglycoside Amikacin 17 (17.89)






Nitrofuran Nitrofurantoin 40 (42.11)
Quinolones/ Fluoroquinolones Ciprofloxacin 58 (61.05)
Nalidixic Acid 77 (81.05)
Norfloxacin 61 (64.21)
Ofloxacin 59 (62.11)
Sulfonamide Co-Trimoxazole 59 (62.11)
Tetracycline Doxycycline 56 (58.95)
Table 2 Microbiological profile of urinary isolates
Isolates Number (%)
Gram positive Coagulase-negative staphylococci 18 (12.77)
S. aureus 15 (10.64)
Enterococcus spp 8 (5.67)
Sub total 41 (29.08)
Gram negative E. coli 67 (47.52)
Klebsiella spp 24 (17.02)
Proteus spp 3 (2.13)
Citrobacter spp 1 (0.71)
Pseudomonas spp 2 (1.42)
Neisseria spp 3 (2.13)
Sub total 100 (70.92)
Total 141 (100)
Table 4 MDR trend in Enterobacteriaceae family
Organisms Total number MDR strains (%)
E. coli 67 64 (95.52)
Klebsiella spp 24 24 (100.00)
Proteus spp 3 3 (100.00)
Citrobacter spp 1 1 (100.00)
Total 95 92 (96.84)
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plasmids [4]. Out of 14 antibiotics used, 11 were found
effective to only less than half of the isolates. Majority
(96.84 %) of Enterobacteriaceae isolates were found to
be MDR. Thakur et al. [21] has observed 64.04 % MDR
Enterobacteriaceae and 73.68 % MDR E. coli isolates.
The widespread use of antibiotics could be associated
with the selection of antibiotic resistance mechanisms in
pathogenic and non pathogenic isolates of E. coli [22].
MDR isolates were more in females than in males and
common in age group ≥ 61 years.
Over the past few years, the prevalence of ESBL pro-
ducing strains among clinical isolates varies greatly with
different geographic regions and rapidly changing over
time [23]. In this study, phenotypically 18 (26.87 %) iso-
lates were confirmed as ESBL producers E. coli isolates.
ESBL positive E. coli was distributed equally among male
and female. Highest number of ESBL producers E. coli
was obtained from the patients of age above 60 years.
Other studies have also shown that ESBL isolates are en-
countered more frequently in the elderly, according to
Roshan et al. [24], Shah et al. [25] and Rajan and Prabav-
athy [26] majority of isolates were from patients between
40 to 70 years, 50 to 60 years and 51 to 70 years respect-
ively. The ESBLs-producing E. coli were most frequent
in older age group in this study; it can be due to the rea-
son that older patients are immunocompromised and
more prone to infections by resistant organisms [27].
Nosocomial infections caused by ESBL producing patho-
gens are associated with risk factors such as elderly age,
prolonged hospitalization, previous antibiotic use, and
presence of invasive devices [28].
All ESBL positive E. coli strains were resistant to cefo-
taxime, ceftazidime and ceftriaxone. This outcome is in
agreement with the study done by Islam et al. [29]. Simi-
larly all E. coli isolates were resistant to cefotaxime and
ceftriaxone in a study by Sompolinsky et al. [30] and to
ceftazidime and ceftriaxone in a study by Chander and
Shrestha [6]. High percentage of resistance to cefotaxime
(99.2 %), ceftazidime (99.2 %) and ceftriaxone (99.5 %)
was observed by Wani et al. [31]. ESBL positive isolates
also showed high degree of resistance to other antibi-
otics like cefalexin, norfloxacin, cefixime, nalidixic acid,
ciprofloxacin and ofloxacin. Aminoglycosides have good
activity against clinically important gram negative bacilli
[32]. Aminoglycosides are very important group of anti-
biotics with activity against many gram-negative rods
Fig. 2 Comparison of ESBL producers and non producers to the antibiotics tested
Table 5 Antimicrobial resistance among ESBL producing E. coli
(n = 18)















Yadav et al. Antimicrobial Resistance and Infection Control  (2015) 4:42 Page 5 of 7
and the most common mechanism of aminoglycoside
resistance is enzymatic modification of antibiotic mol-
ecule. All ESBL positive isolates were sensitive to the
amikacin (100 %) followed by imipenem (94.44 %) and
nitrofurantoin (72.22 %). Antimicrobial resistance sur-
veillance done Nepal Public Health Laboratory (NPHL)
found that ESBL E. coli were susceptible to imipenem
(98.5 %), amikacin (96.1 %) followed by nitrofurantoin
(89.2 %) and chloramphenicol (90.8 %) [33]. Amikacin
and nitrofurantoin can therefore be used effectively against
ESBL producing isolates but these antibiotics have many
limitations. High percentage of isolates were susceptible to
the carbapenem. The study done by Kader and Angamuthu
[34] revealed more than 89 % of the ESBL producers were
susceptible to imipenem and meropenem, whereas Mekki
et al. [35] found 100 % isolates sensitive to the carbapen-
ems. The production of β-lactamase may be of chromo-
somal or plasmid origin [4, 36]. Plasmid mediated
production is often acquired by transfer of genetic in-
formation from one organism to another. Such trans-
ferable plasmid also codes for resistant determinants
to antimicrobial agents other than β-lactams [37]. Hence
multidrug resistance is expected to be more common in
ESBL producing organisms.
The production of ESBL pathogens like E. coli has an
important clinical importance. It has been well recog-
nized that poor outcome occurs when patients with ser-
ious infections due to ESBL-producing organisms are
treated with antibiotics like cephalosporins and penicil-
lins to which the organisms are resistant. The mortality
rate in such patients is significantly higher than in pa-
tients treated with antibiotics to which the organism is
susceptible. All patients with antibiotics failure either die
or have continued sign of infections, which necessitates
change in antibiotic [38]. Microbiology laboratories can
play an important role in detecting and promptly report-
ing the isolation of ESBL-positive bacteria, since drug sus-
ceptibility data are important for the clinical management
of patients infected by these organisms [39]. Clinicians,
whose laboratories do not perform tests for detection of
ESBLs, and report ESBL producers as resistant to cephalo-
sporins, risk poor outcome for their patients infected with
ESBL producing organisms. The detection of ESBLs in
any clinical isolate has great potential significance from
the point of view of infection control [38].
This study also has some limitations; the study was
carried out in a hospital. The picture of the study does
not necessarily reveal the picture of the whole country,
therefore systematic prospective surveillance should be
carried covering wide geographical region in order to
obtain information on seasonal, geographical and
ethnic variation of pathogens and their antibiotic sus-
ceptibility profile. Moreover, characterization of ESBL
strains should be performed genotypically, so that the
information can be used in fighting with increasing re-
sistance to antimicrobials.
Conclusion
The present study looked at the ESBL production in E.
coli isolates in National Kidney Center in Kathmandu,
Nepal. Using the phenotypic confirmatory test forwarded
by the CLSI, relatively significant E. coli isolates tested
were ESBL producers. Multidrug resistance to the antibi-
otics tested was also seen more among ESBL producer
than the non-producers. In this study Enterobacteriaceae
isolates showed significant resistance to the commonly
prescribed drugs. In the present study 96.84 % Entero-
bacteriaceae were found to be multidrug resistant and
26.87 % E. coli were ESBL producers. These findings
suggest for further study in this field including the con-
sequences of colonization with multidrug resistant and
ESBL-producing bacteria both in the community and in
the hospital setting. These findings also suggest incorp-
orating early detection mechanism of ESBL by clinical
setting so that appropriate antibiotics can be used and
this will also help in controlling increasing multidrug re-
sistance due empirical therapy. With the spread of ESBL
producing strains in hospitals all over the world, it is ne-
cessary to know the prevalence of ESBL positive strains
in a hospital so as to formulate a policy of empirical
therapy in high risk units where infections due to resist-
ance organisms is higher.
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